ArticleJAC-antimicrobial resistance2026
Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a lack of standard data on the frequency of carbapenem-resistant Gram-negative bloodstream infections (CR-GNBSI) in haematology wards compared to other hospital units, as well as the factors that increase the risk of acquiring one. Methods: Retrospective observational study of GNBSI in haematological patients conducted from January 2019 to December 2022. The primary outcome was the incidence proportion (IP) of CR-GNBSI in the haematology ward and its incidence proportion ratio (IPR) compared with the rest of the hospital wards. Secondary outcomes included the identification of risk factors associated with CR-GNBSI in two cohorts: haematological patients with GNBSI and a case-control cohort of febrile neutropenia (FN). Results: The IP of CR-GNBSI in the haematology ward was 6.12 per 1000 admissions, while its IPR in relation to the rest of the hospital wards was 6.83 (95% CI 3.80-11.46; Conclusions: The haematology ward has a significantly higher IP of CR-GNBSI compared to the other hospital wards. The performance of risk factors for CR-GNBSI varies significantly depending on the cohort under study.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.